RAVICHANDRAN ASHWIN says it's too early to comment on Rahul Dravid's coaching style but the premier India spinner is confident that happiness will be back in the dressing room under the stalwart's guidance.
Dravid replaced Ravi Shastri in the Indian set-up, beginning his stint with the ongoing India-New Zealand Twenty20 series.
Ashwin is back in the Indian limited-overs squad after spending four years on the sidelines. Since mid-2017 the spinner did not get to play a single white-ball game and even warmed the benches in team's recent England Test tour.
The 35-year-old made a comeback at the recently concluded T20 World Cup when he played against Afghanistan and is now part of the team that is clashing with New Zealand, taking two wickets in the series opener.
"It's too early for me to comment on Rahul Dravid's coaching style, but he's put the hard yards in through the U-19 level," Ashwin told official broadcaster after India's five-wicket win on Wednesday (17).
"He won't leave much to chance, and he'll be all about preparation and process, so that we can bring the happiness back into the Indian dressing room," he added.
India has a new leadership in place with Dravid taking over from Shastri and Rohit Sharma replacing Virat Kohli as captain in T20Is.
Talking about the first T20, Ashwin said he realised that taking the pace off the ball was working wonders.
"The slower you bowled, there was more purchase you got on this pitch. If you hit the seam and tossed it up, it did do things like Santner showed in the second innings," he said.
"It's tricky in T20s, you can't miss your lengths and you don't know when to toss it up but here it did help to give it some air."
Given a manageable 165-run target, Ashwin thought that they will cross the line quite early and the match would not drag to the final over.
"It was a slightly under-par score and we thought 170-180 would be par. We thought we would cruise home around the 15th over, but that's T20 cricket for you.
"I bowled the first over in the powerplay, and figuring out the pace to bowl is important and it took me some time to figure that out.
"It's about varying the pace and knowing when to vary it. It's important to take each of the 24 balls as an event, and look at each ball in isolation and as an opportunity," he said.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.